|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||27.55 - 27.91|
|52 Week Range||24.02 - 29.93|
|PE Ratio (TTM)||363.95|
|Earnings Date||Apr 25, 2018 - Apr 30, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||31.63|
Boston Scientific Corp. said it has agreed to acquire NxThera Inc., the developer of a treatment for benign prostatic hyperplasia.
NxThera also will spin out a yet-to-be-named startup that will target the prostate cancer market.
MARLBOROUGH, Mass., March 21, 2018 /PRNewswire/ -- Boston Scientific (BSX) today announced that it has entered into a definitive agreement to acquire NxThera, a privately-held company based in Maple Grove, Minnesota. NxThera developed and commercialized, in the United States (U.S.) and Europe, the Rezūm® system which is a minimally invasive therapy in a growing category of treatment options for men with symptoms arising from of benign prostatic hyperplasia (BPH). The transaction consists of an upfront cash payment of $306 million, and up to an additional $100 million in potential commercial milestone payments over the next four years. Boston Scientific has an existing minority investment in NxThera, which is expected to result in a net upfront payment of approximately $240 million upon closing and milestone payments of up to $85 million.
BARCELONA, Spain and MARLBOROUGH, Mass., March 20, 2018 /PRNewswire/ -- Boston Scientific Corporation (BSX) announced real-world data from the TRUE-HD study during a late-breaking clinical trial session today at the annual congress of the European Heart Rhythm Association (EHRA) in Barcelona, Spain. The global TRUE-HD study examined procedural process, acute success and safety for the mapping and ablation of various clinical arrhythmias.
A firestorm in cardiology resulted when a major NIH-funded clinical trial changed its design and moved the goalposts just before reaching completion.
Dentsply Sirona (XRAY) updated its estimates and assumptions during fiscal 2Q17 and underwent an annual impairment test of goodwill. According to company estimates, the goodwill charges associated with some of its technologies segment businesses, including CAD-CAM imaging and its treatment center, came from impairment. The company recorded nearly $1.1 billion in goodwill impairment charges in 2Q17 and $581 million in 4Q17, for a total of ~$1.67 billion in fiscal 2017. Meanwhile, the company undertook an annual impairment assessment of indefinite-lived intangible assets.
The Retirement Systems of Alabama manages assets that totaled $38.4 billion at Sept. 30, 2016, for state pensions and trusts. RSA also owns a number of prominent real-estate properties, including Manhattan skyscraper 55 Water Street and the Robert Trent Jones Golf Trail, a collection of courses. The manager’s largest investment however is in domestic stocks, and as of Dec. 31 it had $20.7 billion invested in U.S.-traded securities.
MARLBOROUGH, Mass. , March 14, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 17th Annual Needham Healthcare Conference on Tuesday, March 27, 2018 in ...
MARLBOROUGH, Mass. , March 12, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced key data presentations that will be featured at the annual congress of the European Heart Rhythm ...
As of March 7, 2018, Abbott Laboratories (ABT) was trading at a forward PE (price-to-earnings) ratio of 20.8x, while the stock has a PE ratio of 59x. The forward estimate is lower than the current PE ratio, which reflects the analysts’ expectations for higher company earnings over the next 12 months. To calculate the forward PE for a company, the current stock price of the company is divided by its earnings estimates for the next 12 months.
On March 6, 2018, Abbott Laboratories (ABT) announced that it received FDA (US Food and Drug Administration) approval for its Masters HP 15-mm rotatable mechanical heart valve, which is the first and only heart valve developed for newborns and infants. The trial included patients five years and under who had damaged, diseased, or malfunctioning heart valves. On March 6, 2018, ABT stock rose ~0.86%, whereas Medtronic (MDT), Boston Scientific (BSX), and Edwards Lifesciences (EW), which are the other major players in the structural heart device business, saw gains of ~0.83%, ~0.04%, and ~1.2%, respectively.
Stock Monitor: AxoGen Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 07, 2018 / Active-Investors.com has just released a free research report on Boston Scientific Corp. (NYSE: BSX ). If you want ...